5 FU

DRUG8 trials

Conditions

Ampullary CancerBiliary Tract CancerCholangiocarcinomaColorectal CancerGallbladder CancerLiver MetastasesMetastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

CompletedNCT05546853

University Hospital, GrenoblePancreatic Ductal Adenocarcinoma

Start: 2023-03-28End: 2025-06-16Updated: 2026-02-06

Phase 2

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

CompletedNCT00448136

Hoffmann-La RocheNeoplasms

Start: 2007-07-31End: 2011-11-30Updated: 2015-01-22

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

WithdrawnNCT00577109

Hoffmann-La RocheColorectal Cancer

Start: 2007-12-31End: 2012-06-30Updated: 2018-07-31

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

CompletedNCT01858649

Cliniques universitaires Saint-Luc- Université Catholique de LouvainMetastatic Colorectal Cancer

Start: 2013-05-31End: 2019-05-31Updated: 2020-10-22

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

RecruitingNCT05472259

Belgian Group of Digestive OncologyMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2022-05-25End: 2027-12-31Target: 134Updated: 2025-02-06

Phase 3

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

CompletedNCT00069108

Hoffmann-La RocheColorectal Cancer

Start: 2003-07-31End: 2006-08-31Updated: 2016-04-01

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

CompletedNCT01926236

The Christie NHS Foundation TrustAmpullary Cancer, Biliary Tract Cancer, Cholangiocarcinoma +1

Start: 2014-02-28End: 2019-01-31Updated: 2020-01-28

Unknown Phase

Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC

WithdrawnNCT01631539

Universitaire Ziekenhuizen KU LeuvenColorectal Cancer, Liver Metastases

Start: 2012-09-30End: 2014-12-31Updated: 2014-12-04

Journal of Clinical Oncology2026-01-10

LAPNet1: Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2025-05-28

Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.

Journal of Clinical Oncology2023-01-245 citations

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

2021-03-30533 citations

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.

2020-11-1674 citations

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

Journal for ImmunoTherapy of Cancer2020-05-01140 citations

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Journal of Clinical Oncology2019-05-20226 citations

Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.

Journal of Clinical Oncology2015-01-20